Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1743 - Hypoxia Gene Expression Defines a Poor Prognostic Sub-group in Oesophageal Adenocarcinoma

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Translational Research

Tumour Site

Oesophageal Cancer

Presenters

Rosalie Douglas

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

R.V. Douglas, C. McKinney, L. Stevenson, L. Cairns, R.D. Kennedy, J.K. Blayney, R.C. Turkington

Author affiliations

  • Queen's University Belfast, Health Science Building, BT9 7BL - Belfast/GB

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1743

Background

The incidence of Oesophageal Adenocarcinoma (OAC) has risen 6-fold in the western world in the last forty years but survival is poor. Increased molecular understanding of this heterogeneous disease is needed to improve treatment selection and develop novel therapies. This study uses gene expression data to perform unbiased molecular subtyping and identify prognostic subgroups in OAC.

Methods

Transcriptional profiling of 274 treatment naïve OAC biopsies was performed using the Almac Diagnostics Xcel array™. All patients received platinum-based neo-adjuvant chemotherapy prior to surgical resection at four United Kingdom centres between 2004-2012. Iterative semi-supervised clustering based on gene expression level variability was performed followed by functional enrichment using DAVID. Cluster membership was assessed for independence of known prognostic factors using Cox proportional hazards regression for relapse-free (RFS) and overall survival (OS). Clustering was repeated with a published 51-gene hypoxia signature with validation in the TGCA OAC (n = 65) and oesophageal squamous cell carcinoma (n = 45) cohorts.

Results

Patients were clustered into two groups with significantly different RFS (HR = 0.54, p = 0.05) and OS (HR = 0.52, p = 0.04). There were no significant differences in known prognostic factors such as pathological response, lymphovascular invasion and resection margin. Pathway analysis revealed the PI3K-AKT, p53, Tumour Necrosis Factor and Hypoxia Inducible Factor 1 (HIF-1) signalling pathway to be upregulated in the poor prognostic group. To further investigate the role of the HIF-1 pathway, a hypoxia 51-gene signature was applied. Patients were stratified into hypoxia low and high groups with improved RFS (HR 0.64, 95% CI 0.42-0.97; p = 0.04) and OS (HR 0.67, 95% CI 0.44-1.02; p = 0.06) in the hypoxia-low group. Increased OS for the hypoxia-low group was also observed in the TCGA cohort (HR 0.49, 95% CI 0.24-0.97; p = 0.04). There was a significant association between membership of the poor prognostic and hypoxia-low cluster groups (p < 0.001).

Conclusions

Molecular stratification and application of a hypoxia gene signature identifies a poor prognostic group of OAC patients characterised by upregulation of hypoxia signalling.

Clinical trial identification

Legal entity responsible for the study

Queen\'s University Belfast.

Funding

Northern Ireland Health and Social Care Research and Development Division.

Editorial Acknowledgement

Disclosure

R.D. Kennedy: Global VP of Biomarker Development for Almac Diagnostics and have patent declarations. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.